Browse > Article
http://dx.doi.org/10.4014/mbl.1611.11001

Glucosylation of Resveratrol Improves its Immunomodulating Activity and the Viability of Murine Macrophage RAW 264.7 Cells  

Pandey, Ramesh Prasad (Department of BT-Convergent Pharmaceutical Engineering, Sun Moon University)
Lee, Jisun (Department of Biotechnology, The Catholic University of Korea)
Park, Yong Il (Department of Biotechnology, The Catholic University of Korea)
Sohng, Jae Kyung (Department of BT-Convergent Pharmaceutical Engineering, Sun Moon University)
Publication Information
Microbiology and Biotechnology Letters / v.45, no.1, 2017 , pp. 19-26 More about this Journal
Abstract
Effects of resveratrol glucosylation on the immunomodulation properties of resveratrol and on the viability of macrophage cells have been studied by using murine macrophage RAW 264.7 cells. Nitric oxide (NO) and interleukin 6 (IL-6) expression in macrophages in vitro were studied after treatment with different concentrations of (E)-resveratrol, (E)-resveratrol 3-O-${\beta}$-${\small{D}}$-glucoside (R-3-G), or (E)-resveratrol 4'-O-${\beta}$-${\small{D}}$-glucoside (R-4'-G). In vitro viability of RAW 264.7 cells after treatment with the aforementioned three compounds was also studied. As demonstrated by macrophage cell viability assays, two different resveratrol monoglucosides, R-3-G and R-4'-G, exhibited 50-80% reduced cytotoxicity in comparison to (E)-resveratrol in A549 and HepG2 cells. Compared to the resveratrol aglycon, both glucosylated resveratrol derivatives positively modulated NO and IL-6 production in macrophages positively via transcriptionally up-regulating IL-6 and iNOS expression. Conjugation of a glucose moiety on resveratrol was found to enhance the immunomodulating activity of resveratrol and the viability of RAW 264.7 cells.
Keywords
Resveratrol; resveratrol glucosides; RAW 264.7 cells; cell viability; immunomodulation;
Citations & Related Records
Times Cited By KSCI : 2  (Citation Analysis)
연도 인용수 순위
1 Gugler R, Leschik M, Dengler HJ. 1975. Disposition of quercetin in man after single oral and intravenous doses. Eur. J. Clin. Pharmacol. 9: 229-234.   DOI
2 Makino T, Shimizu R, Kanemaru M, Suzuki Y, Moriwaki M, Mizukami H. 2009. Enzymatically modified isoquercitrin, alpha-oligoglucosyl quercetin 3-O-glucoside, is absorbed more easily than other quercetin glycosides or aglycone after oral administration in rats. Biol. Pharm. Bull. 32: 2034-2040.   DOI
3 Tsai SH, Lin-Shiau SY, Lin JK. 1999. Suppression of nitric oxide synthase and the down-regulation of the activation of NFkappaB in macrophages by resveratrol. Br. J. Pharmacol. 126: 673-680.   DOI
4 Wadsworth TL, Koop DR. 1999. Effects of the wine polyphenolics quercetin and resveratrol on pro-inflammatory cytokine expression in RAW 264.7 macrophages. Biochem. Pharmacol. 57: 941-949.   DOI
5 Gao X, Xu YX, Janakiraman N, Chapman RA, Gautam SC. 2001. Immunomodulatory activity of resveratrol: suppression of lymphocyte proliferation, development of cell-mediated cytotoxicity, and cytokine production. Biochem. Pharmacol. 62: 1299-1308.   DOI
6 Choi O, Lee JK, Kang SY, Pandey RP, Sohng JK, Ahn JS, et al. 2014. Construction of artificial biosynthetic pathways for resveratrol glucoside derivatives. J. Microbiol. Biotechnol. 24: 614-618.   DOI
7 Pandey RP, Parajuli P, Koirala N, Lee JH, Park YI, Sohng JK. 2014a. Glucosylation of isoflavonoids in engineered Escherichia coli. Mol. Cells 37: 172-177.   DOI
8 Pandey RP, Parajuli P, Shin JY, Lee J, Lee S, Hong YS, et al. 2014b. Enzymatic biosynthesis of novel resveratrol glucoside and glycoside derivatives. Appl. Environ. Microbiol. 80: 7235-7243.   DOI
9 Mosmann T. 1983. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods. 65: 55-63.   DOI
10 Diehl S, Rincon M. 2002. The two faces of IL-6 on Th1/Th2 differentiation. Mol. Immunol. 39: 531-536.   DOI
11 Detmers PA, Hernandez M, Mudgett J, Hassing H, Burton C, Mundt S, et al. 2000. Deficiency in inducible nitric oxide synthase results in reduced atherosclerosis in apolipoprotein E-deficient mice. J. Immunol. 165: 3430-3435.   DOI
12 Bowe CL, Mokhtarzadeh L, Venkatesan P, Babu S, Axelrod HR, Sofia MJ, et al. 1997. Design of compounds that increase the absorption of polar molecules. Proc. Natl. Acad. Sci. USA 94: 12218-12223.   DOI
13 Zhong M, Cheng GF, Wang WJ, Guo Y, Zhu XY, Zhang JT. 1999. Inhibitory effect of resveratrol on interleukin 6 release by stimulated peritoneal macrophages of mice. Phytomedicine 6: 79-84.   DOI
14 Holtmann H, Resch K. 1995. Cytokines. Naturwissenschaften. 82: 178-187.   DOI
15 Jang M, Cai L, Udeani GO, Slowing KV, Thomas CF, Beecher CW, et al. 1997. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 275: 218-220.   DOI
16 Chan MM, Mattiacci JA, Hwang HS, Shah A, Fong D. 2000. Synergy between ethanol and grape polyphenols, quercetin, and resveratrol, in the inhibition of the inducible nitric oxide synthase pathway. Biochem. Pharmacol. 60: 1539-1548.   DOI
17 Feng YH, Zhou WL, Wu QL, Li XY, Zhao WM, Zou JP. 2002. Low dose of resveratrol enhanced immune response of mice. Acta Pharmacol. Sin. 23: 893-897.
18 Fremont L. 2000. Biological effects of resveratrol. Life Science 66: 663-673.   DOI
19 Fuggetta M, Mattivi F. 2011. The immunomodulating activities of resveratrol glucosides in humans. Recent Pat. Food Nutr. Agric. 3: 81-90.   DOI
20 Gao X, Deeb D, Media J, Divine G, Jiang H, Chapman RA, et al. 2003. Immunomodulatory activity of resveratrol: discrepant in vitro and in vivo immunological effects. Biochem. Pharmacol. 66: 2427-2435.   DOI
21 Baur JA, Sinclair DA. 2006. Therapeutic potential of resveratrol: the in vivo evidence. Nat. Rev. Drug Discov. 5: 493-506.   DOI
22 Neves AR, Lucio M, Lima JL, Reis S. 2012. Resveratrol in medicinal chemistry: a critical review of its pharmacokinetics, drug-delivery, and membrane interactions. Curr. Med. Chem. 19: 1663-1681.   DOI